Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Will Chemours TT segment Adjusted EBITDA margin print below 5% in any quarter of 2026?
Current Prediction
Why This Question Matters
TT segment is already at trough (6% margin FY2025, 52% EBITDA decline, 30% Asia revenue fall). A sustained print below 5% in any 2026 quarter would signal structural impairment and shift CAPITAL_DEPLOYMENT toward divestiture. Four regions of antidumping duties and 1.1M tons of capacity rationalization have not lifted margins, which is itself a negative signal. Tests whether the TT cycle has bottomed or continues to deteriorate.
Prediction Distribution
Individual Predictions(9 runs)
FY2025 TT margin was 6% (trough). Quarterly volatility is typically 3-5 percentage points. Q1 is seasonally weakest; probability Q1 2026 prints below 5% on seasonality alone is ~35-45%. 'Any quarter' criterion gives 4 shots, but quarterly margins are autocorrelated. Joint probability across 4 correlated quarters is materially higher than single-quarter but less than 4x independent. Management 'stable market' guide + Asia -30% + 1.1M ton rationalization that hasn't lifted margins all argue for trough-persistence. 0.40 captures elevated probability with acknowledgment that antidumping duty bite could lift H2 margins.
The key signal is 1.1M tons of rationalization without margin recovery — this is bearish for cyclical bottoming hypothesis. However, management's specific 'stable market' guide (not 'weakening') is revealed-preference against a further leg down. Q1 2026 10-Q timing: the analysis date is 2026-04-22 so Q1 data may be imminent or already flowing. Absence of pre-announce warning suggests Q1 is not dramatically below 6%. Probability of Q1 sub-5% on seasonality ~30-40%, Q2-Q4 each ~25-30% given stable guide. Joint accounting for autocorrelation ~0.36.
Quarterly margin volatility around a 6% trough gives meaningful probability that at least one quarter crosses below 5%. Q1 seasonality is the highest-probability shot (35-45%). Q4 could also be weak if inventory correction returns. Commodity chemicals at trough tend to spend more time below trailing average during cycle bottom. Asia -30% and no volume growth guide reinforce downside. Antidumping duty enforcement timing is uncertain — may not hit margins in 2026. 0.42 reflects committee's CONDITIONAL revenue durability and MIXED capital deployment read.
Math: P(Q1 sub-5%) ~0.35, P(any Q2-Q4 sub-5% conditional on stable market) ~0.20 per quarter. If we assume modest correlation between quarters, P(any 2026 Q sub-5%) ~0.35 + 0.20 + 0.15 + 0.10 (marginal with correlation) = 0.40ish, adjusted to 0.37 for the stable-market guide. Committee's CONDITIONAL classification supports elevated but not high probability.
FY2025 at 6% with 2H-weighted recovery dynamics and antidumping duty effects (building through 2026) could produce 2026 FY margin ~6-8%. Crossing below 5% in any individual quarter requires a specific weak quarter (Q1 seasonality). 0.35 reflects seasonality-driven Q1 probability minus duty-driven recovery lift.
The 'any quarter' framing means a single weak quarter triggers YES. Quarterly volatility at trough is meaningful. 1.1M tons of capacity rationalization without recovery is a strong bearish signal — supports continued trough. Balanced probability 0.40 captures genuine uncertainty about whether TT is at floor or leg-down.
6% FY trough with 3-5pp quarterly volatility and Q1 seasonal weakness gives ~35-45% probability of a sub-5% quarter. 0.38 captures middle.
4 quarterly shots against a 6% FY trough with seasonality; base rate ~0.40. Stable-market guide pulls down slightly; antidumping uncertainty offsets. Settle 0.40.
Base 35-40% reflecting seasonal Q1 + 4 correlated shots + stable guide. Settle 0.37.
Resolution Criteria
Resolves YES if any of Q1 2026, Q2 2026, Q3 2026, or Q4 2026 quarterly disclosures (10-Q filings through Q3 2026; Q4 2026 preliminary results via earnings release) show TT segment Adjusted EBITDA margin below 5.0% (calculated as Adjusted EBITDA / segment net sales). Resolves NO if all four quarters of 2026 print TT Adjusted EBITDA margin at or above 5.0%, or if segment reporting is reorganized/discontinued without a clean TT disclosure in any quarter of 2026.
Resolution Source
Chemours 10-Q filings Q1-Q3 2026, Q4 2026 earnings release or 10-K
Source Trigger
Titanium Technologies (TT) EBITDA Margin — Sustained below 5% signals structural impairment; above 12% implies recovery
Full multi-lens equity analysis